CareDx Acquires Naveris to Enter High-Growth Specialty Oncology Diagnostics
GH•CareDx has acquired Naveris, a developer of oncology imaging tracers, integrating PET imaging agents into its diagnostics pipeline. This strategic move marks CareDx’s entry into high-growth specialty oncology, potentially increasing its addressable market and intensifying competition for Guardant Health.
1. Acquisition Details
CareDx completed its acquisition of Naveris in early July, adding the latter’s proprietary PET imaging tracers for detecting solid tumors. Financial terms were not disclosed, but the deal integrates Naveris’s agent development capabilities into CareDx’s existing R&D operations.
2. Strategic Rationale
The acquisition allows CareDx to extend beyond transplant rejection diagnostics into the estimated multi-billion-dollar specialty oncology imaging market. By combining molecular imaging agents with its laboratory testing platform, CareDx seeks to offer a more comprehensive cancer diagnostic solution.
3. Competitive Implications
This expansion places CareDx in more direct competition with liquid biopsy leaders like Guardant Health, as both firms vie for dominance in oncology diagnostics. The move diversifies CareDx’s revenue streams and could accelerate its market penetration in high-growth oncology segments.
